2 documents found, page 1 of 1
Protective efficacy in a hamster model of a multivalent vaccine for human visce...
Fernández, L; Solana, JC; Sánchez, C; Jiménez, MÁ; Requena, JM; Coler, R; Reed, SG; Valenzuela, JG; Kamhawi, S; Oliveira, F; Fichera, E; Glueck, RVisceral leishmaniasis (VL) is the most severe clinical form of leishmaniasis, fatal if un-treated. Vaccination is the most cost-effective approach to disease control; however, to date, no vaccines against human VL have been made available. This work examines the efficacy of a novel vaccine consisting of the Leishmania membrane protein KMP11, LEISH-F3+ (a recombinant fusion protein, composed of epitopes of the ...
Pre-clinical antigenicity studies of an innovative multivalent vaccine for huma...
Cecílio, P; Pérez-Cabezas, B; Fernández, L.; Moreno, J; Carrillo, E; Requena, J; Fichera, E; Reed, S; Coler, R; Kamhawi, S; Oliveira, F; Valenzuela, JThe notion that previous infection by Leishmania spp. in endemic areas leads to robust anti-Leishmania immunity, supports vaccination as a potentially effective approach to prevent disease development. Nevertheless, to date there is no vaccine available for human leishmaniasis. We optimized and assessed in vivo the safety and immunogenicity of an innovative vaccine candidate against human visceral leishmaniasis...